scholarly journals Preoperative thyroid-stimulating hormone associated risk of differentiated thyroid cancer in patients with thyroid nodules

2021 ◽  
Vol 67 (3) ◽  
pp. 85-91
Author(s):  
Al Essa M
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
Thyroid Nodules ◽  
Conditional Logistic Regression ◽  
Care Center ◽  
Tertiary Care ◽  
Thyroid Stimulating Hormone ◽  
Normal Range ◽  
Tsh Levels ◽  
Stimulating Hormone

In an assessment of risk for differentiated thyroid cancer (DTC) in individuals with human papillary thyroid cancer (PTC) and thyroid nodules a cohort prospective study was undertaken to establish the significance of preoperative thyroid-stimulating hormone (TSH) levels. Confirmed histologically PTC cases in one tertiary care center, and matched healthy individuals were tested for TSH, T3, T4 and T4 free total. The ORs and 95% confidence intervals have been calculated using conditional logistic regression models (CI). The blood TSH levels were related to the higher risk of PTC for men (OR,0,09; 95% Ci, 04–0,21, 95% CI and women) compared with the middle tertile of the TSH levels in the normal range (OR,0,07; 95 percent CI, 0,04–0,1). Over the normal range of TSH levels, an elevated PTC risks were connected amongst women (OR 0,09; 95% CI, 0,04–0,21) but not amongst men (OR,0,07; 95% CI, 0,04–0,1). With an increase in TSH level in the normal range between men and women, the risk for PTC reduced (Ptrend=0.041 and 0.0001). The risk of PTC related to TSH levels has been dramatically elevated above  the normal range for men  and TSH values below the normal range for women.

scholarly journals Observational study on association between serum thyroid stimulating hormone and thyroid malignancy

2017 ◽  
Vol 4 (6) ◽  
pp. 2002
Author(s):  
Arun K. ◽  
Santhosh Nayak K. ◽  
Suhas Gowda
Keyword(s):  
Thyroid Cancer ◽  
Observational Study ◽  
Thyroid Nodules ◽  
Thyroid Stimulating Hormone ◽  
Normal Range ◽  
Advanced Stages ◽  
Test Of Significance ◽  
Serum Tsh ◽  
Tsh Levels ◽  
Stimulating Hormone

Background: Thyroid cancer is the most common endocrine malignancy and its incidence continues to rise. Thyroid carcinoma in most cases presents clinically as a solitary nodule or as a dominant nodule within a multinodular thyroid gland. There are a number of well-established of predictors of malignancy in thyroid nodules. More recently studies have suggested that higher concentration of TSH, even within the normal range are associated with subsequent diagnosis of thyroid cancer in patients with thyroid nodules and even higher serum TSH levels have been found associated with advanced stages of thyroid cancer. Objectives were to determine the association between serum thyroid stimulating hormone (TSH) concentration and thyroid cancer and to estimate serum TSH levels in different stages of thyroid malignancy.Methods: A hospital based observational study was conducted in a tertiary care hospital for a period of 2 year. 120 patients presenting with thyroid nodule without an overt thyroid dysfunction during the study period were included in the study. Chi-square was used as test of significance. Independent t test was the test of significance for quantitative data between two groups.Results: In the study majority of thyroid cancer patients (106 out of 120) had serum TSH concentrations ranging 1.71mIU/L-5.5mIU/L i.e. within normal range but towards higher range. Mean serum TSH concentrations was significantly high in advanced stages of carcinoma. Mean Serum TSH was high in Stage III and Stage IV (5.17±1.36mIU/l) compared to stage I and II (4.03±1.87mIU/l).Conclusions: The study concludes that TSH levels were in the Upper reference range in majority of thyroid malignancies and high levels of serum TSH concentrations associated with advanced stage of thyroid cancer.

scholarly journals Analyzing the relationship between differentiated thyroid cancer and thyroid autoimmunity: an exploratory study from tertiary care center in South India

2019 ◽  
Vol 6 (8) ◽  
pp. 2931
Author(s):  
Zahir Hussain ◽  
Rakesh Chandru Kaharin ◽  
Muhamed Faizal Ayub ◽  
Jabamalai Ferdinant ◽  
Smitha S. Rao
Keyword(s):  
Thyroid Cancer ◽  
Differentiated Thyroid Cancer ◽  
South India ◽  
Care Center ◽  
Tertiary Care ◽  
Endocrine Surgery ◽  
Thyroid Autoantibodies ◽  
Tertiary Care Center ◽  
Benign Group ◽  
Tsh Levels

Background: Differentiated thyroid cancer (DTC) is the most common endocrine malignancy. There is a rising incidence of DTC over the past few decades. This dramatic increase in incidence may be due to increased detection rate or because of factors like thyroid stimulating hormone (TSH) or thyroid autoantibodies which remains unclear. Our study aims to analyze the association between DTC and thyroid autoimmunity.Methods: This was a retrospective study over 1 year conducted at the department of endocrine surgery, Madras medical college, a tertiary care center in South India. During the study period, 364 total thyroidectomies were performed which includes 292 benign and 72 malignant cases. Among malignancies, 15 non-DTC cases were excluded from the study. Finally, we included 57 patients with DTC and 114 patients with benign disease (randomly chosen age and sex-matched controls) for analysis. Demographic data, TSH levels, antithyroglobulin (anti-TG), and anti-thyroid peroxidase (anti-TPO) antibody levels, histopathology were recorded and analyzed.Results: Histopathological examination revealed 47.4% of DTC and 63.2% of benign cases has associated thyroiditis. In our study elevated anti-TPO and anti-TG antibodies were not significantly associated with DTC (anti-TPO positivity 75.4% in DTC group vs. 74.6% in benign group, p=0.90, anti-TG antibody positivity 66.7% in DTC vs. 67.5% in benign group, p=0.90). Also, no significant association established between elevated TSH and DTC.Conclusions: Association between thyroid autoantibodies and DTC has been evaluated in several studies with inconsistent results. The present study did not show any significant associations between elevated thyroid autoantibodies, TSH levels, and DTC.

scholarly journals Comparative study on association between serum TSH concentration and Thyroid cancer

2017 ◽  
Vol 4 (8) ◽  
pp. 2800
Author(s):  
Prasad C. ◽  
Supreet Kumar ◽  
Tej Tej Y.
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Nodules ◽  
Tertiary Care ◽  
Follicular Carcinoma ◽  
Thyroid Stimulating Hormone ◽  
P Value ◽  
Thyroid Malignancy ◽  
Tertiary Care Centre ◽  
Serum Tsh ◽  
Tsh Levels

Background: In India, thyroid cancer accounts for less than 1% of all malignancies (2% of women and 0.5% of men). Thyroid cancer is responsible for 6 deaths per 1 million persons annually. Serum TSH is a well-established growth factor for thyroid nodules, however its role in thyroid malignancy is inconclusive hence this study was conducted with the objective to determine the association between serum Thyroid stimulating hormone (TSH) concentrations with thyroid carcinoma.Methods: Case control study was conducted in a tertiary care centre. 120 Benign and malignant thyroid subjects respectively were included in the study. Newly diagnosed and record based data collection was done. Measurements of serum TSH concentrations were performed by automated immune chemiluminescent assay. Data was analyzed using SPSS 22 version software, Chi-square test was used as test of significance for qualitative data, p value of <0.05 was considered as statistically significant.Results: Majority of them were females in the age group 26 to 40 years in both the groups and were diagnosed to have solitary thyroid nodule. In malignant thyroid nodules 51.7% were diagnosed to have follicular carcinoma, 46.7% had papillary carcinoma and 1.7% were diagnosed to have Hurthle cell carcinoma. Significant association was observed between TSH levels and diagnosis of thyroid lesions. TSH was raised (>4mIU/L) in 46.6% of malignant nodules and in 15% of benign nodules. Raised TSH had an odds ratio of 4.958 for Thyroid malignancy compared to benign nodulesConclusions: Higher TSH levels were associated with Thyroid malignancy and the risk of malignancy rises in parallel with serum TSH within normal range, and high levels of serum TSH concentrations was associated with advanced stage of thyroid cancer. 

scholarly journals Utility of pre-operative serum thyroid stimulating hormone in predicting thyroid malignancy

2017 ◽  
Vol 4 (8) ◽  
pp. 2796
Author(s):  
Arun K. ◽  
Santhosh Nayak K. ◽  
Suhas Gowda
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Nodules ◽  
Thyroid Stimulating Hormone ◽  
Multinodular Goitre ◽  
Advanced Stages ◽  
Test Of Significance ◽  
Thyroid Malignancies ◽  
Serum Tsh ◽  
Tsh Levels ◽  
Stimulating Hormone

Background: Thyroid cancer is the most common endocrine malignancy and its incidence continues to rise. Thyroid carcinoma in most cases presents clinically as a solitary nodule or as a dominant nodule within a multinodular thyroid gland. There are a number of well-established of predictors of malignancy in thyroid nodules. More recently studies have suggested that higher concentration of TSH, even within the normal range are associated with subsequent diagnosis of thyroid cancer in patients with thyroid nodules and even higher serum TSH levels have been found associated with advanced stages of thyroid cancer. The objective of this study was to determine the serum thyroid stimulating hormone (TSH) concentration before surgery in different thyroid malignancies and to compare serum TSH concentration after surgery in thyroid malignancyMethods: A hospital based observational study was conducted in a tertiary care hospital for a period of 2 year. 120 patients presenting with thyroid nodule without an overt thyroid dysfunction during the study period were included in the study. Chi-square was used as test of significance. Independent t test was the test of significance for quantitative data between two groups.Results: Mean serum TSH was higher in thyroid malignancies and significant difference was observed between solitary and multinodular goitre. Mean serum TSH concentrations was significantly high in papillary carcinoma and advanced stages of carcinoma. Mean serum TSH was high in stage III and stage IV (5.17±1.36 mIU/l) compared to stage I and II (4.03±1.87 mIU/l).Conclusions: The study concludes that TSH levels were high in thyroid malignancies arising from multinodular goitre, majority of thyroid malignancies had high levels of serum TSH concentrations and TSH was high with advanced stage of thyroid cancer 

scholarly journals Association between Thyroid-Stimulating Hormone Level after Total Thyroidectomy and Hypercholesterolemia in Female Patients with Differentiated Thyroid Cancer: A Retrospective Study

2019 ◽  
Vol 8 (8) ◽  
pp. 1106 ◽  
Author(s):  
Young Ki Lee ◽  
Hokyou Lee ◽  
Seunghee Han ◽  
Hyein Jung ◽  
Dong Yeob Shin ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Total Thyroidectomy ◽  
Differentiated Thyroid Cancer ◽  
Ldl Cholesterol ◽  
Density Lipoprotein ◽  
Recurrence Risk ◽  
Thyroid Stimulating Hormone ◽  
Metabolic Derangement ◽  
Tsh Suppression ◽  
Tsh Levels

Less-intense TSH suppression strategies can be used for differentiated thyroid cancer (DTC) patients with a low recurrence risk, but their metabolic outcomes are not well known. We aimed to evaluate changes in the serum cholesterol levels and the risk of hypercholesterolemia according to postoperative TSH levels in 1092 female DTC patients receiving levothyroxine after total thyroidectomy. The preoperative-to-follow-up change in total cholesterol (TC) levels in the TSH level <0.03, 0.03–0.3, 0.3–2, and 2–5 mIU/L groups was −3.69 mg/dL (p = 0.006), +0.13 mg/dL (p = 0.926), +12.46 mg/dL (p < 0.001), and +16.46 mg/dL (p < 0.001), respectively. When compared with TSH levels of 0.03–0.3 mIU/L, those of 0.3–2 mIU/L were found to be associated with hypercholesterolemia (adjusted odds ratio (AOR) = 1.86 and 5.08 for TC 200–240 and ≥240 vs. <200 mg/dL) and hyper-low-density lipoprotein (LDL)-cholesterolemia (AOR = 2.76 for LDL-cholesterol ≥160 vs. <130 mg/dL). Additionally, TSH levels of 2–5 mIU/dL were associated with hypercholesterolemia (AOR = 2.85 and 6.95 for TC 200–240 and ≥240 vs. <200 mg/dL) and hyper-LDL-cholesterolemia (AOR = 2.08 and 4.17 for LDL-cholesterol 130–159 and ≥160 mg/dL vs. <130 mg/dL). In patients with normal TSH level maintenance following thyroidectomy, TC levels markedly increased, resulting in an increased hypercholesterolemia prevalence. Metabolic derangement risk due to insufficient levothyroxine replacement should be considered in the adoption of less-intense TSH suppression strategies, postoperatively, in DTC patients.

Sign in / Sign up

Export Citation Format

Share Document